MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Trial Details

NCT ID

NCT06277154

Phase

PHASE2

Sponsor

HRYZ Biotech Co.

Status

RECRUITING

Cancer Type

Liposarcoma Sarcoma

Interventions

• MASCT-I
• Doxorubicin
• Ifosfamide

Locations (sample)

• Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

• Age≥18 years and≤70 years;
• According to WHO Classification of Tumours, 5th Edition, Volume 3: Soft Tissue and Bone Tumours, histopathologically or cytologically confirmed unr…
• No previous treatment with systematic chemotherapy or targeted therapy for advanced soft tissue sarcomas or whose disease progressed after 6months …
• At least one measurable and assessable lesion defined by RECIST 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.